D J Pettibone

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

B. E. Evans, M A Jacobson, M. Bock, 1999, Bioorganic & medicinal chemistry letters.

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.

R M Freidinger, D S Perlow, M T Guidotti, 1998, Bioorganic & medicinal chemistry letters.

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

D. Veber, R. Freidinger, D. Reiss, 1995, Journal of medicinal chemistry.